Answers are grounded in this paper and cite their sources.
Demonstrates that nitric oxide-propelled nanomotors induce ferroptosis and stiffen tumor cells in mice, indicating a mechano-immunotherapy strategy for cancer.
Despite the tremendous therapeutic promise of activating immunogenic ferroptosis, it can prime robust de novo T cell responses, and biomechanically mediated immune suppression desensitizes the cytotoxicity of T cells against tumor cells. Herein, we developed a nitric oxide (NO)-propelled nanomotor (GFS@CAF) that co-delivers a ferroptosis inducer (GFS) and a cholesterol scavenger (β-cyclodextrin) to increase the sensitivity of tumors to ferroptosis immunotherapy by targeted deep penetration into tumor and depleting cholesterol to stiffen tumor cells. GFS@CAF nanomotors utilize the high level of H 2 O 2 in the tumor microenvironment to generate NO, enabling self-propulsion and deep penetration into tumor by chemotaxis. GFS@CAF elevates reactive oxygen species levels and inactivate glutathione peroxidase 4, thereby promoting lipid peroxide accumulation to trigger immunogenic ferroptosis and initiate T cell responses. Meanwhile, membrane-anchored cyclodextrin depletes cholesterol to overcome the mechanical softness of cancer cell, which further enhances cytotoxic T lymphocyte-mediated cytotoxicity. In Hepa1-6 subcutaneous tumor-bearing mouse model, we successfully demonstrated that GFS@CAF led to significant tumor regression and established a durable immunological memory, with these mice surviving for two months. This study highlights the mechano-immunotherapeutic potential of combining via cholesterol depletion and immunogenic ferroptosis for tumor treatment. Overall, our work presents a feasible approach for initiating robust T-cell-mediated anti-tumor killing in cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: